NUBEQA (darolutamide)

NUBEQA (darolutamide)

SELF-ADMINISTERED - ORAL

Indications for Prior Authorization:

• Treatment of patients with non-metastatic castration-resistant prostate cancer

Patients must meet the following criteria for the indications(s) above:

• Prescribed by or in consultation with an oncologist, AND
• Diagnosis of non-metastatic castration-resistant prostate cancer (progression after either GnRH therapy or bilateral orchiectomy), AND
• Patient will receive a gonadotropin-releasing hormone (GnRH) analog concurrently or has had bilateral orchiectomy

The following conditions do not meet the criteria for use as established by WHA P&T committee:

• All non-FDA approved uses not listed in the approved indications

Dosing:

• 600 mg twice daily

Approval:

• 1 year